These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 29614278

  • 1. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J, Parker P, Mokhtari N, Di Sarno R, Saccone G, Berghella V.
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [Abstract] [Full Text] [Related]

  • 2. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC, Locci M, Saccone G, Gragnano E, Berghella V.
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [Abstract] [Full Text] [Related]

  • 3. Effects of progestogens in women with preterm premature rupture of membranes.
    Di Sarno R, Raffone A, Saccone G.
    Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
    [Abstract] [Full Text] [Related]

  • 4. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Suhag A, Saccone G, Berghella V.
    Am J Obstet Gynecol; 2015 Oct; 213(4):479-87. PubMed ID: 25797233
    [Abstract] [Full Text] [Related]

  • 5. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM, Lewis DF.
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [Abstract] [Full Text] [Related]

  • 6. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA, Garite TJ, Maurel K, Abril D, Das A, Clewell W, Heyborne K, How H, Huang W, Lewis D, Lu G, Miller H, Nageotte M, Porreco R, Sheikh A, Tran L, Obstetrix Collaborative Research Network.
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [Abstract] [Full Text] [Related]

  • 7. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB, McIntire DD, Leveno KJ.
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [Abstract] [Full Text] [Related]

  • 8. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D, Moore RM, Mercer BM, Mansour JM, Mesiano S, Schatz F, Lockwood CJ, Moore JJ.
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [Abstract] [Full Text] [Related]

  • 9. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC, Sheffield J, Graham EM.
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [Abstract] [Full Text] [Related]

  • 10. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 11. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 12. Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis.
    Boelig RC, Della Corte L, Ashoush S, McKenna D, Saccone G, Rajaram S, Berghella V.
    Am J Obstet Gynecol MFM; 2019 Mar; 1(1):50-62. PubMed ID: 31172132
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction within or after 12 hours of ≥36 weeks' prelabor rupture of membranes: a systematic review and meta-analysis.
    Bellussi F, Seidenari A, Juckett L, Di Mascio D, Berghella V.
    Am J Obstet Gynecol MFM; 2021 Sep; 3(5):100425. PubMed ID: 34153513
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Saccone G, Suhag A, Berghella V.
    Am J Obstet Gynecol; 2015 Jul; 213(1):16-22. PubMed ID: 25659469
    [Abstract] [Full Text] [Related]

  • 18. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC, Gyamfi-Bannerman C, Biggio JR, Chauhan SP, Hughes BL, Louis JM, Manuck TA, Miller HS, Das AF, Saade GR, Nielsen P, Baker J, Yuzko OM, Reznichenko GI, Reznichenko NY, Pekarev O, Tatarova N, Gudeman J, Birch R, Jozwiakowski MJ, Duncan M, Williams L, Krop J.
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, Connan L, Vayssière C, Langer B, Capelle M, Azimi S, Porcher R, Rozenberg P, Groupe de Recherche en Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.